Predict your next investment

HEALTHCARE | Biotechnology
achillion.com

See what CB Insights has to offer

Founded Year

1998

Stage

Acq - P2P | Acquired

Total Raised

$110.65M

Valuation

$0000 

About Achillion Pharmaceuticals

Achillion is a biopharmaceutical company engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders.On January 28th, 2020, Achillion Pharmaceuticals was acquired by Alexion at a valuation of $930 million.

Achillion Pharmaceuticals Headquarter Location

300 George Street

New Haven, Connecticut, 06511,

United States

203-624-7000

Latest Achillion Pharmaceuticals News

Jnana Therapeutics Announces Promotion of Joel Barrish, Ph.D., to President and Chief Scientific Officer

Nov 2, 2021

– Company co-founder and scientific leader will drive future growth of chemoproteomic product engine and pipeline programs – November 02, 2021 07:00 AM Eastern Daylight Time BOSTON--( BUSINESS WIRE )-- Jnana Therapeutics , a biotechnology company utilizing its next generation chemoproteomic platform to target well-validated but hard-to-drug targets, today announced the promotion of Joel Barrish, Ph.D., a co-founder of the company, to President and Chief Scientific Officer from his previous role as Chief Scientific Officer. Since co-founding Jnana, Dr. Barrish has led the research team in the creation of RAPID, the company’s high throughput screening-enabled chemoproteomic platform fueling its pipeline and partnership deals. He was instrumental in the evolution of the RAPID platform, initially deployed to target the solute carrier (SLC) family of metabolite transporters, to an expanded set of protein classes that have been considered hard-to-drug with small molecules. Dr. Barrish also led the advancement of the company’s pipeline, including its lead program in preclinical development designed to provide a novel oral approach to address phenylketonuria (PKU) by inhibiting the SLC transporter SLC6A19. “Joel’s exceptional expertise and leadership have been critical for building our RAPID platform and pipeline, R&D organization and company strategy,” said Joanne Kotz, Ph.D., co-founder and Chief Executive Officer of Jnana Therapeutics. “We congratulate him on this well-deserved promotion to lead the important next stage of Jnana’s growth, unlocking previously undruggable targets to improve the lives of patients.” Dr. Barrish co-founded Jnana in 2017 and has served as the company’s Chief Scientific Officer since its inception. Dr. Barrish joined Jnana from Achillion Pharmaceuticals, where he served as Chief Scientific Officer. Prior to Achillion, he had a nearly 30-year career at Bristol-Myers Squibb which culminated in global leadership of discovery chemistry across therapeutic areas. In that role, he worked with teams responsible for advancing more than 40 compounds into clinical development. His leadership resulted in notable achievements in kinase inhibitor drug discovery in immunology and cancer, including Sprycel (dasatinib), which he co-invented. About RAPID RAPID (Reactive Affinity Probe Interaction Discovery) is Jnana’s proprietary, high throughput screening-enabled chemoproteomic platform used to discover small molecules to address undruggable targets with unprecedented speed and efficiency. This next generation platform enables the discovery of any druggable site - orthosteric and allosteric - across the surface of a target protein by assessing the binding of small molecule ligands to the protein in its endogenous biological context in live cells. Once druggable sites have been discovered, RAPID utilizes a high-throughput screen against a library of drug-like molecules to efficiently identify chemical matter as the starting point for a drug discovery program About Jnana Therapeutics Jnana Therapeutics is a biotechnology company utilizing RAPID to address well-validated but hard-to-drug targets, including the solute carrier (SLC) family of metabolite transporters. Jnana is focused on developing best-in-class therapies to treat a wide range of diseases, including rare and immune-mediated diseases and cancer. Headquartered in Boston, Jnana is founded by world-renowned scientists and backed by leading life science investors. For more information, please visit www.jnanatx.com and follow us on Twitter and on LinkedIn . Contacts

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Achillion Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Achillion Pharmaceuticals is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Achillion Pharmaceuticals Patents

Achillion Pharmaceuticals has filed 77 patents.

The 3 most popular patent topics include:

  • Complement system
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/29/2019

8/10/2021

Complement system, Immune system, Immunology, Clusters of differentiation, Rare diseases

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/29/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/10/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Complement system, Immune system, Immunology, Clusters of differentiation, Rare diseases

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.